The dominant story this week is megacap tech selling off, but underneath that headline, companies in old-economy sectors are quietly crushing their numbers. A steel maker surging 16% on a strong outlook and a hospital chain beating expectations both sugge

Verdict: a real edge trapped behind a terrible entry — wait

This is a well-backtested momentum strategy with a genuine edge — the 60-month THC backtest shows a 61.1% win rate across 18 trades and a 17.1% cumulative return, improving to 63.6% over the trailing 24 months — but the trade is not actionable today. Both CLF and THC are extended well past their EMA crossover entry points, with THC already flashing an RSI of 88.2 that would trigger the strategy's own exit rule. The deeper problem is that the basket's returns are almost entirely THC carrying the load while CLF drags with a -4.6% gross margin, -8.5% operating margin, and -$1.02B in free cash flow, making this less a diversified old-economy play than a single hospital bet with a structurally uncorrelated hedge that is bleeding. The 22.3% maximum drawdown on the backtested equity curve, combined with exits filled on daily bars rather than intrabar data, means realized risk in volatile post-earnings sessions could be worse than the numbers suggest. **Conviction breakdown:** Backtest evidence is moderate given the solid THC-centric win rate but limited sample of 18 trades. Fundamentals trend splits sharply — THC's 16.5% operating margin and 99th-percentile free cash flow are strong, but CLF's negative margins and deteriorating balance sheet are a clear drag. Risk quality is constrained by the deep drawdown and approximate exit fills. Thesis support is only partial because the diversification narrative masks concentration in one return-generating name. Trade readiness is low because neither ticker is in its entry zone and THC is already past its exit trigger. | Dimension | Score | |---|---| | Backtest evidence | 58 | | Fundamentals trend | 35 | | Risk quality | 40 | | Thesis support | 45 | | Trade readiness | 20 |

Trade now

**Action today: wait.** Neither name is in its entry zone. The strategy fires when the 9-day EMA crosses above the 21-day EMA alongside an ADX reading above 25 and a close above VWAP. On CLF, the 9-day EMA sits at $11.70 versus the 21-day at $11.15 — already $0.55 past the crossover — while on THC the spread is even wider at $16.84 above the trigger. ADX is firmly met on both (64.9 for CLF, 61.6 for THC), but the crossover event has already happened and the strategy does not chase extended moves. For CLF, last close is $12.29 with nearest support at $12.26 and resistance at $13.00. The fixed stop loss triggers at a 2.3% decline (roughly $12.01) and take-profit at a 4.7% gain (roughly $12.87), giving an effective reward-to-risk ratio of about 2:1 once entry conditions are met. For THC, last close is $254.13 with support at $250 and resistance at $222.82; the same percentage stops translate to roughly $248.27 on the downside and $266.07 on the upside. "Wait" means something concrete here: set alerts on both tickers for a 9-day EMA crossing back below the 21-day EMA followed by a fresh upward crossover. The strategy needs that re-convergence — the 9-day dipping toward or below the 21-day before crossing back above — to generate a new signal. Right now both names are running too hot to offer the clean entry the rules demand. The 60-month backtest on THC produced a 17.1% return across 18 trades with a 61.1% win rate and a 22.3% maximum drawdown, so the edge is real but the drawdown path is punishing. No robust parameter setup was established, so the published rules stand as-is without nearby optimization.

Post-Earnings Momentum Has Real Historical Legs

The idea's core claim is that old-economy earnings surprises generate tradeable momentum, and the backtested evidence on Tenet Healthcare (THC) supports that thesis directly. Over a 60-month evaluation window, the EMA/ADX/VWAP crossover strategy on THC produced 18 trades with a 61.1% win rate and a cumulative return of 17.1%. That is a meaningful edge for a momentum-driven rule set, and it lines up with the idea's argument that post-earnings drift in overlooked names can persist for days. The fundamental picture for THC reinforces why these momentum triggers have been firing productively. Tenet posted $21.3B in revenue for its latest fiscal year, growing 3.1% year-over-year, with operating income of $3.5B translating to a 16.5% operating margin — placing it in the 90th percentile among Health Care peers. Free cash flow of $2.53B puts THC in the 99th percentile of its sector cohort. Per the Yahoo Finance piece on July 24, Tenet's second-quarter earnings and guidance both topped forecasts, which is exactly the kind of catalyst this strategy is designed to capture. The backtest also shows improvement in more recent conditions. Over…

Scores

• Conviction score breakdown: 40
• Thesis support: 45
• Trade readiness: 20
• Risk quality: 40
• Backtest evidence: 58
• Fundamentals trend: 35

Watch items

• CLF — EMA (9) vs EMA (21) crossover
• THC — EMA (9) vs EMA (21) crossover
• THC — RSI (14)
• CLF — RSI (14)
• CLF — ADX (14)
• THC — ADX (14)
• CLF — EMA (9) crossed above EMA (21)
• CLF — ADX (14) above 25
• CLF — ADX (14) above 20